Monitoring cognitive impairment through speech

Winterlight has developed a tablet-based assessment that is fast, objective, and stress-free. By analyzing speech alone, we can detect cognitive impairment associated with dementia and mental illness. Our assessment can be used in life science research, senior care and clinical settings.

A biomarker for clinical research

Paper-based cognitive assessments are slow, subjective and often coarse. Winterlight has developed a speech-based cognitive assessment that analyzes short snippets of speech and uses AI to objectively measure cognition via hundreds of vocal biomarkers in speech and language. Winterlight can support clinical trials and studies for a wide range of central nervous system disorders.

Work with us

Tracking cognitive wellness in senior care

It is challenging to care for seniors with complex medical needs and frequently with cognitive impairments. Combined with your existing health data, we identify seniors at-risk of cognitive or functional decline. Our assessment can help you provide better proactive care at a time when it is most needed to have the greatest impact on the health and happiness of your residents.

Reach us here

Winterlight’s Healthy Aging Study

We are building better tools so that we can identify risk for dementia more quickly and at an earlier age. This will allow researchers to better understand the disease and work towards a cure. If you are healthy and 50 years or older in the Greater Toronto Area, we would like your help on learning the effect of the aging process on the brain..

Tell me more

Developed in partnership with:



What's new

April 7, 2021

ISCTM conference features Winterlight research on validation of automated speech assessments

Winterlight labs presented two research posters at the International Society for CNS Clinical Trials and Methodology (ISCTM) virtual annual meeting highlighting validation studies of their automated speech assessment technology.

Read Read More
November 4, 2020

Winterlight presents new research on longitudinal speech changes in Frontotemporal Dementia at CTAD

Winterlight Labs presented two research posters at the 2020 Clinical Trials on Alzheimer's Disease (CTAD) virtual meeting, highlighting new work on longitudinal speech and language changes in Frontotemporal Dementia and Alzheimer's Disease.

Read Read More
October 20, 2020

Winterlight publishes framework and review of evaluation of speech-based biomarkers

Winterlight Labs published a paper on evaluation and validation of speech-based digital biomarkers in the journal Digital Biomarkers.

Read Read More
September 24, 2020

Winterlight is developing tools to characterize depression subtypes and symptoms based on speech

Winterlight Labs presented research on crowdsourced speech data collection for developing speech biomarkers for depression at the International Society for CNS Clinical Trials and Methodology (ISCTM) virtual autumn conference.

Read Read More

Get in touch

Mailing Address

Winterlight Labs
46 Hayden St
Suite 400
Toronto
Ontario, Canada
M4Y 1V8

Send us a message